Literature DB >> 22065291

Prognostic role of CA15.3 in 7942 patients with operable breast cancer.

M T Sandri1, M Salvatici, E Botteri, R Passerini, L Zorzino, N Rotmensz, A Luini, C Mauro, V Bagnardi, M C Cassatella, F Bottari, C Casadio, M Colleoni.   

Abstract

To assess the prognostic value of presurgical CA15.3 in a large cohort of patients with early breast cancer. A total of 7.942 consecutive patients with breast cancer operated at the European Institute of Oncology between 1998 and 2005 and with presurgical values of CA 15.3 available were included. We explored patterns of recurrence by baseline CA 15.3 values. Mean CA15.3 was 17.0 U/ml. CA15.3 was associated with age, tumor size, nodal involvement, Ki-67 labeling index, grade, HER2 expression, molecular subtype, and perivascular invasion. CA15.3 was independently associated with distant metastases [HR > 20 U/ml vs. ≤ 20 U/ml: 1.34 (95% CI 1.15-1.56)] and death [HR > 20 U/ml vs. ≤ 20 U/ml: 1.30 (95% CI 1.11-1.53)]. When considering CA15.3 as continuous variable, we observed a constant risk of metastasis and death from the lowest values to about 15-20 U/ml, and then a significantly increasing risk with increasing values of CA15.3. Finally, CA15.3 provided significant additional information to the common prognostic factors to predict the occurrence of metastases (C-index P value 0.04). In patients with operable breast cancer, presurgical CA15.3 value is an independent prognostic factor for metastases and deaths. CA15.3 provides additional information to the common prognostic factors and should be considered in the adjuvant therapeutic algorithm.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22065291     DOI: 10.1007/s10549-011-1863-x

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

1.  CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.

Authors:  Brigitte Rack; Julia Jückstock; Elisabeth Trapp; Tobias Weissenbacher; Marianna Alunni-Fabbroni; Amelie Schramm; Peter Widschwendter; Krisztian Lato; Thomas Zwingers; Ralf Lorenz; Hans Tesch; Andreas Schneeweiss; Peter Fasching; Sven Mahner; Matthias W Beckmann; Werner Lichtenegger; Wolfgang Janni
Journal:  Tumour Biol       Date:  2016-08-01

2.  Elevated preoperative serum cancer antigen 15.3 levels are associated with reduced disease-free survival: a single-institution experience.

Authors:  Eyad Fawzi Alsaeed; Huda Abdulkarim; Mutahir A Tunio
Journal:  Breast Cancer (Dove Med Press)       Date:  2013-07-26

3.  Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients.

Authors:  Amir Bahrami-Ahmadi; Fariborz Makarian; Mohammad R Mortazavizadeh; Mohammad F Yazdi; Mehdi Chamani
Journal:  J Res Med Sci       Date:  2012-09       Impact factor: 1.852

4.  CA15.3 serum concentrations in older women with infiltrating ductal carcinomas of the breast.

Authors:  Álvaro Ruibal; Pablo Aguiar; María Carmen Del Río; María Elena Padín-Iruegas; José Ignacio Arias; Michel Herranz
Journal:  Int J Mol Sci       Date:  2014-10-31       Impact factor: 5.923

5.  Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.

Authors:  Michiko Imamura; Takashi Morimoto; Takashi Nomura; Shintaro Michishita; Arisa Nishimukai; Tomoko Higuchi; Yukie Fujimoto; Yoshimasa Miyagawa; Ayako Kira; Keiko Murase; Kazuhiro Araki; Yuichi Takatsuka; Koshi Oh; Yoshikazu Masai; Kouhei Akazawa; Yasuo Miyoshi
Journal:  World J Surg Oncol       Date:  2018-02-12       Impact factor: 2.754

6.  MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients.

Authors:  Hanna Huebner; Lothar Häberle; Volkmar Müller; Iris Schrader; Ralf Lorenz; Helmut Forstbauer; Visnja Fink; Fabienne Schochter; Inga Bekes; Sven Mahner; Julia Jückstock; Naiba Nabieva; Andreas Schneeweiss; Hans Tesch; Sara Y Brucker; Jens-Uwe Blohmer; Tanja N Fehm; Georg Heinrich; Mahdi Rezai; Matthias W Beckmann; Peter A Fasching; Wolfgang Janni; Brigitte Rack
Journal:  Cancers (Basel)       Date:  2022-03-28       Impact factor: 6.639

7.  Prognostic Models for Nonmetastatic Triple-Negative Breast Cancer Based on the Pretreatment Serum Tumor Markers with Machine Learning.

Authors:  Huihui Chen; Shijie Wu; Jun Hu; Kun Zhang; Kaimin Hu; Yuexin Lu; Jiapan He; Tao Pan; Yiding Chen
Journal:  J Oncol       Date:  2021-05-15       Impact factor: 4.375

Review 8.  Molecular markers for breast cancer: prediction on tumor behavior.

Authors:  Bruna Karina Banin Hirata; Julie Massayo Maeda Oda; Roberta Losi Guembarovski; Carolina Batista Ariza; Carlos Eduardo Coral de Oliveira; Maria Angelica Ehara Watanabe
Journal:  Dis Markers       Date:  2014-01-28       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.